294 related articles for article (PubMed ID: 21305545)
1. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
[TBL] [Abstract][Full Text] [Related]
2. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
[TBL] [Abstract][Full Text] [Related]
3. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine.
Webb MS; Saxon D; Wong FM; Lim HJ; Wang Z; Bally MB; Choi LS; Cullis PR; Mayer LD
Biochim Biophys Acta; 1998 Jul; 1372(2):272-82. PubMed ID: 9675310
[TBL] [Abstract][Full Text] [Related]
5. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
Li CL; Cui JX; Wang CX; Zhang L; Li YH; Zhang L; Xiu X; Li YF; Wei N
Int J Pharm; 2010 May; 391(1-2):230-6. PubMed ID: 20214962
[TBL] [Abstract][Full Text] [Related]
6. Development of a stable single-vial liposomal formulation for vincristine.
Mao W; Wu F; Lee RJ; Lu W; Wang J
Int J Nanomedicine; 2019; 14():4461-4474. PubMed ID: 31296986
[No Abstract] [Full Text] [Related]
7. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L
J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385
[TBL] [Abstract][Full Text] [Related]
8. The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity.
Zhu G; Oto E; Vaage J; Quinn Y; Newman M; Engbers C; Uster P
Cancer Chemother Pharmacol; 1996; 39(1-2):138-42. PubMed ID: 8995511
[TBL] [Abstract][Full Text] [Related]
9. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
[TBL] [Abstract][Full Text] [Related]
10. The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate.
Zhang J; Chen Y; Li X; Liang X; Luo X
Int J Nanomedicine; 2016; 11():4187-97. PubMed ID: 27616886
[TBL] [Abstract][Full Text] [Related]
11. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention.
Zhigaltsev IV; Maurer N; Akhong QF; Leone R; Leng E; Wang J; Semple SC; Cullis PR
J Control Release; 2005 May; 104(1):103-11. PubMed ID: 15866338
[TBL] [Abstract][Full Text] [Related]
13. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
[TBL] [Abstract][Full Text] [Related]
14. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
15. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
Johnston MJ; Semple SC; Klimuk SK; Edwards K; Eisenhardt ML; Leng EC; Karlsson G; Yanko D; Cullis PR
Biochim Biophys Acta; 2006 Jan; 1758(1):55-64. PubMed ID: 16487476
[TBL] [Abstract][Full Text] [Related]
16. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y
J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556
[TBL] [Abstract][Full Text] [Related]
17. High drug payload curcumin nanosuspensions stabilized by mPEG-DSPE and SPC: in vitro and in vivo evaluation.
Hong J; Liu Y; Xiao Y; Yang X; Su W; Zhang M; Liao Y; Kuang H; Wang X
Drug Deliv; 2017 Nov; 24(1):109-120. PubMed ID: 28155567
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded polymeric nanoparticles based on PCL-PEG-PCL: preparation, in vitro and in vivo evaluation.
Zhang L; He Y; Yu M; Song C
J Control Release; 2011 Nov; 152 Suppl 1():e114-6. PubMed ID: 22195789
[No Abstract] [Full Text] [Related]
19. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation.
Gill KK; Nazzal S; Kaddoumi A
Eur J Pharm Biopharm; 2011 Oct; 79(2):276-84. PubMed ID: 21575719
[TBL] [Abstract][Full Text] [Related]
20. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
